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ABSTRACT
Bicuspid aortic valve disease is the most common congenital cardiac disorder, being present in 1% to 2% of the general population. Associated aortopathy is a
common finding in patients with bicuspid aortic valve disease, with thoracic aortic
dilation noted in approximately 40% of patients in referral centers. Several previous consensus statements and guidelines have addressed the management of
bicuspid aortic valve–associated aortopathy, but none focused entirely on this disease process. The current guidelines cover all major aspects of bicuspid aortic
valve aortopathy, including natural history, phenotypic expression, histology
and molecular pathomechanisms, imaging, indications for surgery, surveillance,
and follow-up, and recommendations for future research. It is intended to provide
clinicians with a current and comprehensive review of bicuspid aortic valve aortopathy and to guide the daily management of these complex patients. (J Thorac
Cardiovasc Surg 2018;156:e41-74)

Typical patient with BAV and associated aortopathy.
Central Message
The current document is the full online-only
version of ‘‘The American Association for
Thoracic Surgery Consensus Guidelines on
Bicuspid Aortic Valve–Related Aortopathy.’’
Perspective
BAV-related aortopathy is a common clinical
entity. An increasing amount of literature has
recently shown that BAV aortopathy is less
dangerous than previously described. The current document is a comprehensive review of
BAV-related aortopathy and its management.
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1. INTRODUCTION
Bicuspid aortic valve (BAV) disease is the most common
congenital cardiac disorder, being present in 1% to 2% of
the general population.1 Associated aortopathy is a common finding in patients with BAV disease, with thoracic
aortic dilation noted in approximately 40% of patients in
referral centers.2 The risk of acute aortic emergencies,
most commonly aortic dissection, is higher in patients
with BAV disease than in the general population.3 Optimal
timing of surgical intervention, to avoid aortic emergencies,
is defined as that time point when the risk of conservative
management exceeds the risk of surgery. However, precise
determination of this time point is difficult and depends on
several factors, including patient age, risk factors, comorbidities, family history, and presence or absence of significant aortic valvular disease.
Historically, aortopathy observed in patients with BAV
disease was thought to be no different than that associated
with tricuspid aortic valve (TAV) disease. That is, aortic
dilation was thought to be due to turbulent blood flow downstream from a stenotic aortic valve. In the 1990s and 2000s,
however, several observations and studies led investigators
to think that a strong genetic role contributed to BAVassociated aortopathy and that the risk of acute aortic
complications was substantially increased in this patient
population.4 Such hypotheses led to recommendations for
a more aggressive surgical approach to this disease, with
some suggesting that BAV aortopathy was roughly equivalent to Marfan syndrome.5 Subsequent studies and observations have led to a middle ground, however, suggesting that
hemodynamic and genetic components play varying roles in
different subgroups of patients with BAV6 and that the risk
of aortic emergencies is not as high as previously thought in
this patient population.7,8 Determination of the cause of
BAV aortopathy is important because of the therapeutic
implications for patients with isolated aneurysmal dilation
of the aorta and in those undergoing aortic valve surgery
for BAV disease.
Several previous documents have addressed the management of BAV-associated aortopathy, with the first being a
set of multisocietal guidelines published in 2010.5 This document made aggressive recommendations for the management of BAV aortopathy, grouping such patients in with
Marfan and other connective tissue disorders. However, multiple studies reported since that time have provided new insights into the pathophysiology and mechanistic aspects of
BAV aortopathy. As such, a more conservative set of recommendations was made in the more recently published
valvular heart disease guidelines by the American Heart Association (AHA) and the American College of Cardiology
(ACC).9 The marked difference in the positions of these 2
sets of guidelines resulted in the recent publication of a clarification statement.10 The European Society of Cardiology
(ESC) also published guidelines on the management of
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valvular heart disease in 201211 and aortic disease specifically in 2014.12 Both of these documents contained more
conservative recommendations for BAV aortopathy, in line
with the 2014 ACC/AHA guidelines.
Of these publications, none focused entirely on patients
with BAV aortopathy. Therefore, the current consensus
statement differs in that it covers all major aspects of
BAV aortopathy, including its natural history, phenotypic
expression, histology and molecular pathomechanisms, imaging, indications for surgery, surveillance and follow-up,
and recommendations for future research. Such research
will hopefully lead to new insights into this common disease and the need for an update to the current consensus
statement in a few years.
BAV aortopathy is a markedly heterogeneous entity. Dilation may occur in the aortic root, the tubular ascending aorta,
the proximal aortic arch, or any contiguous combination of
these 3.13 The current document uses the term ‘‘aortic root’’
to refer to the proximal aorta extending from the nadir of
the aortic annulus to the sinotubular junction (STJ) including
the coronary ostia. For purposes of consistency, the term
‘‘tubular aorta’’ (also known as the ‘‘supracoronary aorta’’)
is used to describe the area between the STJ and the takeoff
of the brachiocephalic artery. The ‘‘aortic arch’’ refers to
the area extending from the brachiocephalic to the left subclavian artery. In addition, the Sievers’ classification14 is used to
describe BAV morphology (Figure 1). Although several
different classification systems have been used to describe
BAV morphology, the Sievers’ system is the one that is
used most commonly within the cardiac surgery literature.
However, it is clear that a more comprehensive classification
system that takes into consideration BAV morphology, BAV
pathology (ie, stenosis, insufficiency, or mixed), and location
and extent of associated BAV aortopathy is required.
Because BAV aortopathy is a relatively common disorder, decisions regarding its therapeutic management must
be made by cardiovascular clinicians on a regular basis.
Despite this, there is significant confusion within the cardiovascular community regarding appropriate decisionmaking in this patient population.15 The confusion is not
surprising, however, given the described differences in recommendations made by various societies and the shifting
discussion on the cause and pathophysiology of BAV aortopathy. The purpose of this consensus statement is to provide clinicians with a current and comprehensive review
of all major aspects of BAV aortopathy and to serve as a
guide in the daily management of these complex patients.
2. EPIDEMIOLOGY AND NATURAL HISTORY
A. Epidemiology
Aortic enlargement and aneurysm formation, especially
in the ascending aorta, are part and parcel of BAV disease—the so-called bicuspid aortopathy.

I. Prevalence
The prevalence of BAV in the general population is
known to be 1% to 2%.1,16-20 Hoffman and Kaplan1 report
a prevalence in this range based on ‘‘unselected consecutive
necropsies,’’ which they consider the ‘‘standard’’ for detection. This makes BAV the most common congenital anomaly affecting the human heart (if one excludes tiny muscular
ventricular septal defects that close spontaneously by 1 year
of age). It is said that BAV accounts for more morbidity and
mortality than all other congenital heart lesions combined.18,21 This mortality may be incurred via multiple
disease mechanisms: aortic stenosis (AS), aortic
insufficiency (AI), or ascending aortic aneurysm and
dissection. Male patients are thought to predominate, by a
margin of approximately 2 to 1.22 It has been shown in a
single-center experience that 50% of all aortic valve operations performed on patients aged more than 50 years are
done for BAV disease.23 Likewise, 50% of all valve operations performed in patients with coarctation of the aorta can
be attributed to BAV disease.24
Although these statistics are staggering, the true burden of
BAV disease may be grossly underestimated, because it may
remain asymptomatic in childhood and even into adulthood,
so that no imaging studies are indicated or performed.25
II. Likelihood of aneurysm development in patients
with bicuspid aortic valve disease
Multiple studies have quantified the risk over time of development of dilatation of the ascending aorta (to a size of 4.04.5 cm) in patients with BAV. These studies indicate that
20% to 30% of patients with BAV develop aneurysmal
enlargement during a follow-up of 9 to 25 years.26-28 A
recent review article suggests that up to 84% of patients
with BAV may ultimately develop an aneurysm (based on 8
individual studies). The risk of aneurysm development was
found to be 80-fold higher than for the general population.28
III. Aneurysm location
Heterogeneity is the rule in terms of the segment of the
ascending aorta involved by bicuspid aneurysm.26 The
tubular ascending aorta is most commonly involved
(60%-70% of bicuspid aneurysms), although all segments,
including the aortic root and the aortic arch, can be involved
(Figure 2). There is evidence that the ‘‘root phenotype’’ of
BAV aortopathy, in which the predominant dilatation is at
the level of the sinuses of Valsalva, represents a more malignant and rapidly progressive aortopathy (Section 3.C).29-32
The marked heterogeneity of BAV-associated aneurysm
location is distinctly different from other common types
of ascending aortic aneurysms. Degenerative aneurysms
tend to start in the mid-ascending aorta and then progress
distally and proximally, whereas those associated with connective tissue disease are usually confined to the aortic root.
BAV morphology and pathology seem to play a role in
determining where the BAV-associated aneurysm is located
(Section 3).
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FIGURE 1. Sievers’ classification system for BAVas viewed from the surgeon’s side with the left coronary artery at left. The number of specimens is given,
and the percentage is shown in parentheses. The blackened lines represent raphe. The main category is based on the number of raphes, the first subcategory is
based on spatial position, and the second subcategory reflects valve function. Ap, Anterior-posterior; B, balanced valvular lesion; I, insufficiency; L, left
coronary sinus; lat, lateral; N, noncoronary sinus; No, normal function; R, right coronary sinus; S, stenosis. Used with permission from Sievers and
Schmidtke.14

IV. Major role in causation of aortic dissection
An important point to note is the large number of aortic
dissections associated with BAV aortopathy. Although
only 5% or less of patients with BAV will have aortic
dissection over a lifetime,21 BAV disease affects 1 in every
50 to 100 human beings. Thus, not only the better appreciated Marfan syndrome but also BAV is an important cause
of aortic dissection.3 However, recent studies have found
substantially lower rates of aortic dissection in patients
with BAV than previously determined, especially in
younger patients.27,33 For instance, in a recent study by
Itagaki and colleagues,7 the rate of aortic dissection in patients with BAV 15 years after aortic valve replacement
(AVR) was 0.55% and not significantly different from patients with TAV (0.41%). However, patients with Marfan
syndrome had a substantially higher rate of aortic dissection
(5.5%) that was significantly greater than the rate in patients with BAV or TAV (P <.001).
V. Genetics
Although there is a definite genetic component to BAV disease, the precise patterns of inheritance have been elusive.
Approximately 9% to 15% of first-order family members
also have BAV disease, with men and women equally affected
e44

within those families.34-36 These percentages are higher than
in the general population (1%-2%), demonstrating the
influence of genetics in this disease. Missense mutations in
the NOTCH1 gene have been implicated in some patients
with BAV disease.37-39 The vital NOTCH signaling pathway,
involved in differentiation of multiple organs (including
skeletal muscle, central nervous system, pancreas, and blood
vessels), is highly evolutionarily conserved (ie, in humans,
mice, and zebrafish).40 High evolutionary conservation indicates critical pathways whose aberration is likely to lead to significant or life-threatening disease. NOTCH genes play an
important role in familial bicuspid valve disease, but they
are found in only 4% of spontaneous cases.41 The variety
and complexity of inheritance of BAVare under intense investigation but remain to be fully clarified.
VI. Associated lesions
Many other lesions and syndromes are strongly associated
with BAV (Table 1). Associated anatomic lesions include
aortic coarctation and patent ductus arteriosus. Coarctationmediated hypertension greatly increases the risk of aortic
dissection.42 In the presurgical era, death from aortic dissection occurred in 19% of patients with BAV, but in 50% of patients with concomitant BAV disease and coarctation.43,44
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FIGURE 2. Anatomic distribution of aortic aneurysms in patients with BAV. BAV, Bicuspid aortic valve. (Aortic Institute at Yale-New Haven, unpublished
data, June 30, 2017.) These data are similar to those reported by Michelena and colleagues.26

Aortic coarctation accompanies BAV more commonly in men
(4:1) than in women.42 Syndromes associated with BAV disease include Turner’s syndrome (monosomy X, characterized
by short stature, lymphedema of the hands and feet, and amenorrhea) and William’s syndrome (abnormal facial appearance,
low nasal bridge, unusually cheerful demeanor). In addition to
those lesions described in Table 1, patients with BAV are also
known to have an increased prevalence of anterior mitral valve
leaflet elongation and prolapse.45,46
B. Natural History
BAV disease can cause morbidity and mortality through the
valve disease (stenosis or insufficiency) or by ascending aortic
aneurysm (leading to aortic dissection or, in rare cases,
rupture). However, recent studies have demonstrated, in the
modern era of diagnosis and care, an overall survival for patients with BAV identical to that of the normal population.26
As long as patients are followed regularly and surgery is
offered in a timely fashion, then the risk of catastrophic aortic
events is low. However, some important observations should
be kept in mind when following patients with BAV.

I. Aortic valve dysfunction is not needed for aortic
dissection to occur
It is important to recognize that neither AS nor AI needs to
be present for aortic dissection to occur.47 In BAV disease,
valvular complications—AS or regurgitation—progress at
their own independent rates, different from the rate of progression of the bicuspid aneurysm. Thus, the lack of AS
does not preclude aortic dissection from occurring. However, patients with BAVand valvular disease (stenosis or insufficiency) are at increased risk of rupture and dissection of the
aorta.48 Evidence increasingly demonstrates regurgitant
BAVs having a more malignant phenotype than stenotic
BAVs, with a higher risk of aortic dissection.49 This topic
will be discussed in more detail in Sections 3 and 6.
II. More malignant behavior of bicuspid aorta?
Many have thought of BAV aortopathy as ‘‘Marfan syndrome light’’—that is, more severe than ordinary aortic
aneurysm disease, but not quite as virulent as the Marfanoid
aorta. Despite the clinical impression that BAV aortopathy
is a malignant actor, supportive concrete evidence has
been elusive.
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TABLE 1. Cardiovascular conditions associated with bicuspid aortic
valve disease
Condition
Coarctation of the aorta

Incidence of BAV
50%

Turner syndrome

30%

Supravalvular AS

30%

Sinus of Valsalva aneurysm

15%-20%

Ventricular septal defect

30%

Shone complex

60%-85%

Ascending aortic aneurysm

Common

Loeys–Dietz syndrome

2.5%-17%

ACTA2 mutation familial thoracic aneurysm
syndrome

3%

Anterior mitral leaflet prolongation/prolapse

Common45,46

BAV, Bicuspid aortic valve; AS, aortic stenosis. Modification of Braverman A. BAV
and associated conditions. Graphic 83657, version 1.0. In: Up-to-Date. Alphen aan
den Rijn, The Netherlands: Wolters Kluwer; 2016. Available at: http://www.
uptodate.com. Accessed June 30, 2017.

A study by Davies and colleagues50 looked for disparities
in behavior between patients with ascending aortic aneurysm with and without BAV disease. Patients with BAV disease presented at a smaller aortic diameter (4.6 vs 4.9 cm for
patients without BAV). Also, their aortas grew more rapidly
than those of patients with TAV: 1.9 mm/year compared
with 1.3 mm/year.50 A higher proportion of patients with
BAV required operative treatment of their aortas (72.8%
vs 44.8%) at a significantly younger age (48.9 vs
63.1 years).50 However, among unoperated patients, there
was no detriment in survival for the bicuspid group, who
actually did better than the TAV group (8.6% vs 25.7%
rate of rupture, dissection, or death at 5 years of followup).50 This likely reflects the substantially younger age at
presentation of the bicuspid group (49 vs 64 years).50 However, in the BAV group, those patients with AS in addition to
the aneurysm had an increased risk of aortic rupture, dissection, or death before operative repair when compared with
patients with a normally functioning bicuspid valve.50
One possible limitation of these data is the fact that they
are derived from a thoracic aortic referral center, and therefore may not accurately reflect the natural history of BAV
aneurysms in the general population.
Other studies have also reported ‘‘mild’’ behavior with near
normal long-term survival and low overall growth rates for the
bicuspid aorta, on the order of 0.4 to 0.6 mm/year, with no differences noted according to specific pattern of leaflet
fusion.29,51 These studies did not find a relationship
between growth rate and original aortic size. The
discrepancies between these studies and the study by
Davies and colleagues50 have several possible explanations.
First, these were studies derived from echocardiographic databases and not from a thoracic aortic referral center, which
may have implications on patient selection bias. Second,
e46
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the investigators may not have adequately imaged the uppermost portion of the ascending aorta in some patients, because
this is a known limitation of echocardiography. Finally, the
patients from the echocardiographic-based studies initially
presented with smaller aortic diameters (4.1 and 3.8 cm)
than those in the study by Davies and colleagues50 (4.6 cm).
III. Medical therapy for bicuspid aortopathy?
It is unclear whether any medical therapy is effective in
preventing adverse events in aortic aneurysms of any
kind, even in the most thoroughly studied Marfan population. Although beta-blockers and angiotensin receptor
blocking drugs are commonly applied to ‘‘protect’’ the
BAV, supportive evidence is lacking.52-54 However, such
agents should be given to patients with documented
hypertension. Statins have been shown to be ineffective,
whereas other studies show a possible protective effect.55
IV. Contemporary clinical outcomes
Contemporary clinical outcomes for patients with BAV
have been summarized in a comprehensive table by Michelena and colleagues28 from the International BAV Consortium (Table 2). Age at presentation, survival, and
likelihood of heart failure, aortic valve surgery, endocarditis, aneurysm formation, aneurysm surgery, and aortic
dissection are described for 8 contemporary clinical studies.
Table 2 demonstrates excellent overall survival of patients
with BAV in community, population-based studies, whereas
outcomes are poorer in referral center patients who have
required AVR. Heart failure is particularly uncommon in
patients with BAV, and AS is a more common indication
for surgery than AI. Aneurysm formation (aortic diameter
>45 mm) occurs in 25% to 45% of patients over prolonged
periods of follow-up, but aortic dissection is a rare event
(1%) outside of tertiary referral center populations, where
it is more common (10%).28
3. PATIENT PHENOTYPES
A. Introduction
Evidence of phenotypic heterogeneity of BAVaortopathy
has emerged in the last decade from several observational
studies and stimulated a critical reappraisal of literature
and treatment recommendations. The hypothesis has been
proposed that different types of BAV aortopathy (ie, socalled aortic phenotypes) may be caused by distinct pathogenetic mechanisms and therefore require individualized
surgical approaches.59,60 In particular, the 2 long-debated
theories on BAV aortopathy pathogenesis, namely, the genetic and the hemodynamic theories, could both be plausible
inasmuch as different phenotypic forms might be subtended
by different contributions of both causative factors. Phenotypic heterogeneity of BAV aortopathy also may explain to
some extent the inconsistencies in published natural history
and follow-up studies, especially regarding the risk of aortic
events in BAV disease. Previous data from mixed BAV
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TABLE 2. Contemporary clinical outcomes in patients with bicuspid aortic valve disease
Study features,
clinical outcomes

Michelena and
colleagues26

Tzemos and
colleagues27

Contemporary clinical outcomes of BAV studies*
Russo and
Michelena and
Davies and
Borger and
colleagues56 colleagues57,z
colleagues33
colleagues50,y

Publication year

2008

2008

2011

2007

2002

Clinical setting

Community,
populationbased

Tertiary
referral
center

Community,
populationbased

Tertiary referral
center

‘Tertiary
referral
center

Inclusion
characteristics

Minimal BAV
dysfunction

Any BAV
dysfunction

Any BAV
dysfunction

Any BAV
dysfunction
with aortic
aneurysm
(mean
baseline
diameter
4.6 mm)

Status
post-AVR

2004

McKellar and
colleagues58
2010

Girdauskas and
colleagues30,x
2012

Tertiary
referral
center

Tertiary
referral
center

Tertiary
referral
center

Status
post-AVR

Status
post-AVR

Status
postisolated
AVR with
aortic aneurysm
(mean baseline
diameter 4.6 mm)

N

212

642

416

70

50

1286

153

Baseline age,
y, mean  SD

32  20

35  16

35  21

49

51  12

56  15

201

58  14

54  11

Follow-up y,
mean  SD

15  6

95

16  7

5

20  2

10  4

12  7

12  3

Survival

90% at 20 y

96% at 10 y

80% at 25 y

91% at 5 y

z40%
at 15 y

67% at 15 y

52% at 15 y

78% at 15 y

Heart failure

7% at 20 y

2%

–

Aortic valve surgery

24% at 20 y

21%

53% at 25 y

Reason for aortic
valve surgery

AS 67%
AR 15%

AS 61%
AR 27%

AS 61%
AR 29%

–

–

–

–

–

68%

–

–

–

–

–

–

–

–

–

Endocarditis

2%

2%

2%

–

4%

Aneurysm formation
(definition, mm)

39%
(>40 mm)

45%
(>35 mm)

26% at
25 y
(45 mm)

–

–

Aortic surgery
(for aneurysm)

5% at 20 y

7%

9%

73%

6%

Aortic dissection

0% at 20 y

1%

0.5% at 25 y

9%

10% at 20 y

2%
9%
(50 mm)
9%
0.5%

–
10%
(50 mm)

–
3%
(50 mm)

1%

3%

1% at 15 y

0%

BAV, Bicuspid aortic valve; AVR, aortic valve replacement; SD, standard deviation; AS, aortic stenosis; AR, aortic regurgitation. *Outcomes reported as percentage only were not
reported within Kaplan–Meier survival analyses. Survival in the first 3 studies26,27,33 was not different than that of the general population. Survival in the study by McKellar and
colleagues58 was inferior to that of the general population, and the rest of the studies were not compared with the general population. yThis study compared patients with BAV with
aneurysms versus patients with TAV with aneurysms. The incidence of aortic dissection was the same for both groups with superior survival in patients with BAVand both groups
with dissection at similar aortic diameters. zThis study suggested that patients with aortic dimension 45 mm or greater at the time of AVR should have the aorta concomitantly
repaired, the basis of the current recommendations. xThis study included consecutive patients with isolated AVR performed for AS only. However, 21 patients with predominant
dilatation of the root (mean diameter, 44 mm) and severe aortic regurgitation who underwent AVR were followed in parallel for a mean of 10 years, and 2 acute dissections
occurred. Reproduced with permission from Michelena and colleagues.28

cohorts resulted in a broad spectrum of surgical treatment
methods being suggested, ranging from very conservative
approaches to very aggressive recommendations, usually
extrapolated from guidelines for management of patients
with connective tissue disorders (eg, Marfan syndrome).5
Although the evidence of BAV aortopathy heterogeneity
has gained increasing recognition in the last decade, data on
individual aortic phenotypes are still scarce. The majority of
published natural history/follow-up studies contain mixed
BAV cohorts and include different stages of BAV disease.
A better understanding of the interaction among morphologic features, functional characteristics of the aortic root,
and transvalvular hemodynamics is required.
Scientific efforts to address the phenotypic heterogeneity
in BAV aortopathy were mainly based on valve-related

factors, including BAV morphology (ie, number and location of fused cusps), functional lesion (ie, stenosis, insufficiency or mixed lesions), and shape/configuration of the
proximal aorta, which are addressed in detail next.
B. Bicuspid Aortic Valve Morphology
As mentioned in the Introduction, BAV morphology is
described throughout this article according to the classification of Sievers and Schmidtke14 (Figure 1). BAV
morphology with fusion of the right-left coronary cusps
(ie, Sievers type I, R/L) and right noncoronary cusp (Sievers
type I, R/N) represents the 2 most common BAV morphologies, accounting for approximately 75% and 20% of clinical cases, respectively.14 Sievers type I L/N and patients
without a raphe (ie, Sievers type 0) are uncommon. The
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low prevalence of these specific fusion morphologies resulted in exclusion of these patients in most case series.
An embryogenetic study by Fernandez and colleagues61
demonstrated that the 2 most common BAV morphologies
(ie, R/L and R/N) develop at different embryonic stages
through distinct mechanisms and therefore should be interpreted as separate etiologic entities. The authors further
suggested that the etiological factors giving rise to the specific BAV morphologies might be involved in the occurrence of distinct forms of BAV aortopathy.61 However, it
is known that both morphologies can frequently appear
within the same pedigree.62
Recent 4-dimensional (4D) flow magnetic resonance imaging (MRI) studies demonstrated that distinct aortic cusp fusion
patterns result in specific orientations of eccentric flow jets
(Figure 3),63-65 which in turn may lead to differential
distributions of aortic wall shear stress (WSS)63,65 and
subsequent focal flow-induced vascular remodeling.64 Eccentric transvalvular flow results in elevated regional WSS at the
right-anterior wall of the proximal aorta for R/L BAV and
right-posterior walls for R/N BAV.65 Bissell and colleagues63
demonstrated more severe flow abnormalities (complex flow,
higher in-plane WSS) and larger aortas in the R/N BAV versus
R/L BAV. However, propagation patterns of transvalvular flow
are still not uniform in patients with BAV with the same cusp
fusion morphology,63-66 and thus the impact of additional
functional parameters (eg, subvalvular components,
geometric orientation of residual aortic valve orifice) has
been postulated.66
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The R/L morphology has been associated with younger
patient age and absence of significant AS or regurgitation,67
whereas a greater prevalence of female patients is observed
in those with R/N.68,69 Regarding the associated aortopathy,
BAV R/L fusion morphology has been linked with
increased diameters of the sinuses of Valsalva.51,68-71 In
contrast, R/N fusion morphology is associated with a
smaller dimension of the aortic root and larger aortic arch
diameters.68-71 However, some authors found no
significant correlation between aortic dimensions and
BAV morphology.72,73 In addition, the published data on
progression of BAV aortopathy in R/L versus R/N fusion
morphologies are inconsistent. Some authors found that
patients with BAV with R/L fusion are at increased risk of
rapid aortic dilatation,71,74 whereas others reported the
same findings in patients with R/N fusion.75 Different statistical approaches and different age ranges of the study populations may explain the differences between studies,
because the 2 types of BAV morphology seem to progress
in an age-dependent manner.69,76 Other studies have
found no correlation between ascending aortic dilatation
rates and BAV morphology.29,51
The data on proximal aortopathy in unicuspid aortic
valve (UAV) disease are limited. Sievers and colleagues77
reported on more extensive aortopathy, including aortic
root and ascending aorta, at a very young age in patients
with UAV disease. Moreover, patients with UAV disease
are more likely to require ascending aortic repair during
their valvular procedure.78 Furthermore, significantly

FIGURE 3. A, Normal aortic valve anatomy with an opening angle of 75 degrees, flow jet angle (q1, which measures displacement of peak systolic flow
[arrow] from vessel midline). B, BAV showing restricted valve opening (opening angle of 60 degrees), displaced flow jet with associated q1, displaced highflow velocities near the vessel wall leading to asymmetrically increased WSS at the aortic convexity. WSS, Wall shear stress. Reproduced with permission
from Burris and Hope.97
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higher expression of GATA5 and endothelial nitric oxide
synthase in the ascending aortas of patients with UAV disease versus BAV and TAV disease has been recently reported.79 Another recent study80 demonstrated decreased
long-term survival in patients with UAV undergoing isolated AVR when compared with patients with UAV who underwent simultaneous aortic surgery.
C. Valve Function
The most common clinical presentation of BAV disease
is calcific AS (BAV-AS), usually presenting between the
fifth and seventh decades of life in both male and female patients. In contrast, pure/predominant BAV AI (BAV-AI)
tends to occur in younger male patients and accounts for
only 10% to 15% cases of BAV lesions in autopsy series.81
Distinct patterns of associated aortopathy have been
observed in BAV-AS versus BAV-AI.47,67,82 Moreover,
differences in histologic and extracellular matrix (ECM)
protein changes,83-85 consistent with the clinical evidence
from post-AVR follow-up studies,86 have also led investigators to suggest different pathobiological mechanisms of
BAV aortopathy for these 2 groups of patients. BAV-AS is
strongly associated with an asymmetric dilatation of the
tubular ascending aorta, which represents the most common
aortic phenotype.47,78,82,87 In contrast, BAV-AI is mainly
accompanied by aortic root dilatation (ie, so-called root
phenotype).78,82,86 However, these associations are not
absolute, and heterogeneity within subgroups of valve
function has been observed.48,82 As stated previously,
BAV aortopathy is a heterogeneous disease.
Aortic dilation observed in patients with normally functioning BAVs has been previously used as an argument for
a genetic origin of BAVaortopathy.48 However, recent experimental in vitro models88 and in vivo 4D flow MRI studies89
demonstrate that even clinically normally functioning BAVs
(ie, without transvalvular pressure gradient or significant
insufficiency) are associated with eccentric transvalvular
flow and asymmetrically increased WSS in the proximal
aorta. Aortic dilatation in normally functioning BAVs occurs
most frequently in the tubular ascending aorta90 and has a natural history that is comparable to their TAV counterparts in
terms of rate of dilatation and occurrence of aortic events.90
D. Shape of the Proximal Aorta
Della Corte and co-authors82 were the first to introduce a
phenotypic classification of the proximal aorta based on the
aortic segment involved and suggested the terms ‘‘root
phenotype’’ and ‘‘ascending phenotype’’ (Figure 4). This
classification system separated patients with BAV with a
possible greater expression of genetically triggered aortopathy (ie, root phenotype) from those with a presumed hemodynamic cause of aortopathy (ie, ascending phenotype).
Other classification systems for the pattern of dimensions
of the different aortic segments have been proposed: Each

of them has merits and flaws, and none can completely
cover the entire spectrum of forms of dilatation.
Four distinct patterns of aortic dilatation in patients with
BAV have been suggested by Fazel and coauthors13 from
Stanford using a model of hierarchical clustering and integrating nonechocardiographic imaging (ie, computed
tomography [CT] scan and MRI). They identified 4 ‘‘clusters’’: aortic root dilatation alone (cluster I), tubular
ascending aorta dilatation alone (cluster II), simultaneous
involvement of the tubular portion and aortic arch (cluster
III), and more diffuse dilatation involving the aortic root,
tubular portion, and aortic arch (cluster IV).13 Cluster IV
was the most frequent pattern of aortopathy; however,
no risk factor analysis or longitudinal data were included.
A slightly modified CT scan–based classification system
of proximal aortic shape has been used by Kang and coauthors,91 confirming the previously reported association
of the atypical morphologies (mainly R/N) with arch
involvement.68
From an echocardiographic analysis, Schaefer and colleagues68 defined 3 shapes of the proximal aorta based on
the relative dimensions of sinuses of Valsalva, STJ, and tubular
segment: type N, with dilation of the sinuses with preservation
of the STJ; type A, dilation of the tubular aorta with preserved
STJ; and type E, dilation of the STJ with preserved sinus of
Valsalva, regardless of the diameter of tubular aorta.
Finally, Park and associates92 proposed a classification
scheme of BAV aortic phenotypes in a surgical study based
on the segment involved (root vs tubular aorta) in the aneurysmal disease. These authors classified ‘‘type I’’ dilatation
as that involving the tubular ascending aorta only, ‘‘type II’’
involving both the tubular ascending aorta and the root, and
‘‘type III’’ confined to the aortic root.92
In a recent longitudinal study that sought to validate the 3
different echocardiography-based BAV phenotypic classifications of the proximal aorta,68,82,92 only the classification
system distinguishing between ascending phenotype and
root phenotype showed a potential prognostic value in
predicting growth rate of the aorta over time.93 Consistent
with these findings, a prior longitudinal study demonstrated
that the root phenotype is associated with a significantly
greater risk of aortic events after isolated AVR.30 This classification system also has practical value, because the root
phenotype frequently requires a Bentall or valve-sparing
procedure, whereas replacement of the tubular aorta is usually sufficient to treat the ascending phenotype (Figure 5).
Of note, 2 aortic dissection series revealed that patients
with BAV received a Bentall operation significantly more
often (85%-94%) than patients with TAV (20%-30%)
because of the presence of a preexisting root aneurysm or
the involvement of the sinuses by the dissecting process.31,32 It should be stressed that although valve
morphology is a congenital feature of a patient with BAV,
the aortic phenotype can change during life. That is, a
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FIGURE 4. Root phenotype versus ascending phenotype of BAV aortopathy. Echocardiographic imaging is shown in the upper left corner, 3-dimensional
reconstruction is shown in lower left corner, and intraoperative findings are shown at right. In the root phenotype, the diameter of the aorta at the level of the
sinuses of Valsalva is greater than that of the tubular ascending aorta, whereas in the ascending phenotype the diameter of the tubular ascending aorta is
greater than that of the sinuses.

proportion of patients with root phenotype can progress to
an ascending phenotype over time.29 Further research in
this area will undoubtedly lead to further insights into
BAV-aortopathy patterns. Hopefully, a single classification
system will emerge that encompasses BAV morphology,
BAV lesion, and location and extent of associated aortopathy in a clinically meaningful manner.
E. Symmetry Versus Asymmetry of Aortic Dilatation
Symmetry versus asymmetry of aortic dilatation also
may provide an important clue regarding the predominant
pathogenesis of BAV aortopathy inasmuch as asymmetrical
aortic involvement might be an indicator of rheological factors involved, whereas symmetrical involvement might be
more predictive of genetically triggered vessel wall weakness. By ‘‘asymmetric dilatation,’’ predominant enlargement of the greater, outer curvature (usually referred to by
the misnomer ‘‘convexity’’ as opposite to the lesser, inner
curvature or ‘‘concavity’’) of the tubular aorta is meant. Preoperative imaging methods can be used to identify asymmetric aneurysms.94,95 Several studies found a significant
correlation between functional BAV lesion (ie, BAV-AS)
and asymmetric dilatation of the tubular aorta.95,96
Asymmetric patterns of histologic lesions and ECM
protein expression have been demonstrated between the
concavity (where less severe changes are observed) and
the convexity (more severe structural changes) in such
patients.66,85 A recent study looked at the expression of
transforming growth factor (TGF) b-1 and matrix
metalloproteinases (MMPs) in BAV aortopathy and found
that wall areas that had been mapped as regions of
increased WSS by preoperative 4D-flow MRI exhibited
greater expression of these markers of vascular
remodeling.64 No similar study has thus far been performed
in patients with BAV-AI.
e50

4. HISTOPATHOLOGIC AND BIOMECHANICAL
FINDINGS OF BICUSPID AORTIC VALVE
AORTOPATHY
A. Histopathologic Studies
BAV aortopathy consists of premature cystic medial
degeneration in approximately one half of surgically

FIGURE 5. Subdivision of proximal aortic involvement in BAV aortopathy. Reproduced with permission from Verma and Siu.18
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excised BAVs.98 Histopathologic changes in the media have
been well documented and specifically delineated for the
BAV-associated aneurysms.85,99-102 It is also well
established that the aortic ECM plays an important role in
maintaining the aorta through both the binding/storing
secreted proteins and maintaining the structural integrity
of the vascular wall.100 The presence of thin, fragmented
elastin fibers, reduced fibrillin-1 content,99 and decreased
types I and III collagen have suggested elevated proteolytic
activity.85,100 The degradation of ECM is under the
balanced control of MMPs and their specific tissue
inhibitors (tissue inhibitors of metalloproteinases
[TIMPs]), which are secreted by vascular smooth muscle
cells (SMCs), fibroblasts, and endothelial cells.103 Various
studies have shown a disturbance in the ECM of surgically
resected BAVs with increased activity of MMPs, with
MMP-1, MMP-2, MMP-9, MMP-12, and MMP-14 (MT1MMP) being most often implicated.104-108 The critical
role of MMP-2 as a key molecular mediator was supported
by a recent meta-analysis.109 Wang and colleagues110
further showed MMP-2 as a circulating biomarker of aortic
dilatation in patients with BAV.
Like MMPs, the expression of TIMPs is controlled during tissue remodeling and physiologic conditions to maintain a balance in the metabolism of the ECM. Studies
have demonstrated increased TIMP-1, TIMP-2, and
TIMP-4 levels associated with BAV aortopathy.107 Altered
MMP/TIMP stoichiometry leads to apoptosis and degeneration of the aortic wall (ie, loss of elastic tissue and SMCs)
and the eventual progression of aneurysms. Of note, histologic grading has revealed more extensive degradation of
the ascending aortic wall in patient with Sievers 1 R/L
fusion.101 This has further been supported with data
showing elevated proteolytic indices (ie, MMP abundance
corrected for TIMP abundance) for MMP-1, MMP-2,
MMP-9, and MMP-12.111 Consistent with findings in patients with Marfan syndrome,112 early data point to the
involvement of TGF-b signaling contributing to the progression of BAV aortopathy, although this remains somewhat controversial.113-115
Phillippi and co-workers116 further characterized the
medial matrix remodeling of the BAVand found unique patterns compared with TAV.116 Grewal and co-workers117
compared the histopathology of BAV, TAV, and Marfan
aortic tissue and found both similarities and differences
among all 3 groups with respect to parameters of matrix remodeling and vascular smooth muscle markers. The
complexity of the histopathologic findings is substantial,
and it is not clear what molecular pathways are unique to
the BAV. The complexity is further confounded by the findings of Heng and colleagues.118 In this recent study, tissue
pathology was compared between TAV and patients with
BAV at matched aortic diameters. At odds with conventional wisdom, more severe histologic abnormalities were

found in TAV compared with BAVs, especially when stratified by diameter.
In addition to ECM degradation, SMC loss is a prominent
feature of BAV aortopathy. SMC phenotype, oxidative
stress patterns, and responsiveness to oxidative stress
appear altered in the BAV wall.115,119-124 Metallothionein,
a free radical scavenger, expression is dysregulated, and
consequent SMC cell viability is reduced in response to
oxidative stress in the BAV. Regional differences in
apoptotic activity also appear to be present comparing the
concave and convex portions of the bicuspid aorta.125 Given
the mounting evidence of regional differences in both the
biology and the biomechanics of BAVaortopathy, it is likely
that they correlate with one another. Aims to leverage these
collective insights toward better diagnostics and risk adjudication are approaching.
B. Biomechanical Studies
Biomechanical functional testing of aortic tissues may
provide further insights into BAV aortopathy. Ascending
aortic wall properties are biomechanically anisotropic.
Despite total collagen and elastin content and histopathologic findings that are similar, microarchitectural and
biomechanical differences are apparent when comparing
aortic wall characteristics in BAV versus TAV. The tensile
strength, particularly in the circumferential and longitudinal
directions, is higher in surgically resected ascending aortas
in BAV compared with TAV,126,127 whereas the
delamination strength of the aortic wall of the BAV is
lower than the TAV.128 Aortic wall remodeling characteristics in patients with BAV also appear distinct with more
highly aligned collagen fibers, more undulating and lessaligned elastin fibers, thinner elastic lamellae, and greater
distances between elastic lamellae.100,116,127,129,130 Aortic
stiffness is associated with progressive aortic dilatation
and aneurysm formation, which is characteristic of BAV
aortopathy.131 A recent study of abdominal aortic aneurysms found that segmental stiffening of the aorta preceded
aneurysm growth and introduced the concept that stiffening
may act as an early mechanism triggering elastin breakdown and aneurysm growth.132 Nonetheless, the evidence
regarding cellular and molecular mechanisms for BAV aortopathy remains complex and contradictory, with a need for
larger cohort, well-controlled studies.
Although stimuli for BAV aortopathy are likely multifactorial, results from recent studies provide strong evidence
that a hemodynamic (ie, rheologic) stimulus, the WSS,
may change local matrix homeostasis and, in turn,
ascending aortic structure and associated functional properties.64,133-137 WSS is known to affect MMP2 levels138 and
has been implicated in the development of aortopathy.89,139
Aortic WSS calculations demonstrate differences in
regional and radial wall stresses,140,141 but how these
differences correspond to aortic wall remodeling, biology,
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and clinical outcome is not yet known. Proof-of-concept
data were recently obtained using a novel ex vivo tissue
model. Atkins and co-workers142 modeled regional WSS
from a TAV compared with a BAV in an ex vivo porcine tissue model, and the impact of BAV-mediated WSS was
determined on aortic wall remodeling. The investigators
found cellular, molecular (ie, increased MMP-2 activity),
and structural changes that are characteristic of human
BAV aortopathy. As highlighted by the investigators, the
study indicates that altered WSS resulting from a BAV
can focally mediate aortic medial degradation. These
unique experimental findings provide compelling support
for an important role of hemodynamics in mediating BAV
aortopathy.
Recent advances in MRI have permitted unobstructed
in vivo assessment of time-resolved 3-dimensional (3D)
blood velocity, using a volumetric technique referred to
as ‘‘4D flow MRI.’’ 4D flow MRI provides the unique
ability to quantify complex 3D blood flow patterns
in vivo and has facilitated new insights and discovery
with respect to complex cardiovascular hemodynamics.65,143-147 Multidimensional 4D flow MRI data (3
spatial dimensions describing 3D velocity over time)
enables aortic blood flow visualization, quantification of
regional flow and velocity,144,148-150 and WSS
quantification.134-137,151,152 Recent MRI studies provide
strong evidence that valve-mediated local flow dynamics143 and regional differences in WSS65 are associated with changes in regional aortic wall histology and
proteolytic events,64 which are known to drive adverse
aortic remodeling. Early studies used less-sophisticated
MRI techniques (2-dimensional [2D] phase-contrast
MRI) to demonstrate BAV-mediated changes in flow
and WSS152 and their association with aortic enlargement.153 Subsequent 4D flow MRI studies have conclusively documented that aortic WSS is increased in
subjects with BAV independent of stenosis severity
when compared with age- and aortic size–matched controls.143 Moreover, regional variation of WSS within
the aorta is dependent on aortic valve fusion phenotype65,143,154 and is associated with aortic diameter.63 A
recent study with 30 patients with BAV and 30 ageappropriate TAV controls provided evidence that altered
aortic hemodynamics may be a pathophysiologic mechanism by which R/L or R/N BAV fusion patterns influence
the expression of aortopathy.65
Similar to the findings of Atkins and Sucosky in the
porcine model, aortic hemodynamic alterations were
found to be related to medial wall degeneration.142 In a
recent study that included both in vivo 4D flow MRI and
aortic tissue resection in 20 patients with BAV, elastin content and structure were severely disrupted in regions of
high WSS with a shift in the expression of specific
MMPs and TGF-b. Girdauskas and colleagues66 found a
e52
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similar correlation between systolic transvalvular flow patterns and proximal aortic wall changes in the setting of
BAV-AS. With more extensive investigation, it is conceivable that quantitative metrics of valve-mediated hemodynamics could be used to guide more precise and
individualized surgical resection strategies beyond
contemporary empirical size thresholds.
5. DIAGNOSTIC MODALITIES
A. General Vascular Imaging Concepts
Transthoracic echocardiography (TTE) is the recommended imaging modality for the initial assessment of
the aortic valve and thoracic aorta, including the assessment of hemodynamic valve function (Table 3; Figures 6
and 7).155 If any part of the examination is not possible
by TTE, CT or MRI is recommended to assess the presence
and extent of aortopathy (Figures 8 and 9). Hemodynamic
valve assessment also can be performed by MRI,156
although TTE remains the gold standard. TTE assessment
of aortic valve function is usually sufficient, but transesophageal echocardiography (TEE) should be performed in
patients with AI that is difficult to quantify with TTE.
BAV-AI may result in an eccentric jet that can be better
visualized with TEE, particularly if patients have lessthan-severe AI by TTE and unexplained left ventricular
dilation or dysfunction. In addition, TEE may best determine the mechanism of AI when aortic valve repair is being considered.
When evaluating the BAV with echocardiography, the
entire thoracic aorta should be assessed: aortic root
(aortic annulus, sinuses of Valsalva, and STJ), tubular
ascending (proximal, mid and distal), aortic arch, and descending thoracic aorta, including diameter measurement
and Doppler assessment for the presence of coarctation
(Table 3 and Figure 10). It is important to recognize
that the term ‘‘aortic root’’ has been loosely used in the
past to include the ascending aorta, and it is critical
that both the components of the aortic root and the
tubular ascending aorta are measured separately and reported as such. The abdominal and pelvic aorta need
not be assessed in isolated BAV disease, unless a family
history of abdominal or iliac aneurysms is present or suspicion of coarctation exists. In addition, although intracranial arterial aneurysms have been found in 10% of
patients with BAV versus 1% of control patients,157 these
are small (ie, <10 mm in diameter), and no increased
prevalence of BAV has been found in patients with intracranial aneurysm–related subarachnoid hemorrhages.158
Therefore, routine brain angiography is not recommended in patients with BAV unless coarctation of the aorta
is present (Table 3).42 Intracranial hemorrhage is a
complication of coarctation of the aorta, independent of
the presence of BAV.
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TABLE 3. Recommendations for initial imaging of the aorta in
patients with bicuspid aortic valve
Recommendation

Class/LOE

TTE is the initial imaging modality of choice for
assessment of the aortic valve and thoracic aorta in
patients with BAV.

I/C5,159

The entire thoracic aorta should be measured by
TTE, reporting each aortic segment separately in
millimeters: root (sinuses of Valsalva), STJ,
tubular ascending aorta (proximal, mid, and
distal), arch, and descending thoracic aorta
(Figure 11). Maximum diameter, regardless of
location, should be reported. Aortic coarctation
should be ruled out with Doppler evaluation of the
descending thoracic aorta and abdominal aorta.

I/C5,159,180

If TTE cannot visualize any aortic segment, any
segment measures 45 mm, or aortic coarctation
cannot be ruled out, recommend assessment of the
entire thoracic aorta with ECG-gated cardiac
MRA or CTA.

I/C33,57

If a patient is undergoing cardiac surgery and root or
tubular ascending aorta measure 40-44 mm by
TTE, recommend assessment of the thoracic aorta
with MRA or CTA before surgery.

I/C33,57,166

If aortic coarctation is present, screening for cerebral
aneurysms is recommended.

I/B180

LOE, Level of evidence; TTE, transthoracic echocardiography; BAV, bicuspid aortic
valve; STJ, sinotubular junction; ECG, electrocardiogram; MRA, magnetic resonance
angiography; CTA, computed tomography angiography.

B. Image Acquisition and Analysis:
Echocardiography, Magnetic Resonance Imaging,
and Computed Tomography
There is no consensus regarding a standard method to
measure and compare aortic measurements across echocardiography, MRI, and CT,159 and different methods are
frequently used within the same institution. Although it is
clear that end-diastolic leading-edge to leading-edge is
the method of choice for TTE in adults,159 no such
consensus exists for CT/MRI. Some advocate enddiastolic outer wall-to-outer wall measurements,5 and
others advocate inner wall-to-inner wall dimensions.159,160
Recent data suggest no systematic measurement bias when
comparing the current echocardiographic method with the
CT/MRI inner wall-to-inner wall method for measuring
the ascending aorta in the absence of root asymmetry.160
Care must be taken when interpreting results across modalities. The maximum diameter observed in the aorta,
regardless of the position in which it is measured, should
be reported in addition to the measurements obtained at predefined anatomic locations (Table 3). In this article, we
recommend the best practices for each modality.
Measurements of the adult thoracic aorta by TTE and
TEE should be obtained in diastole (ie, at the QRS complex)

with the leading-edge to leading-edge technique
(Figure 11).159 For TTE, measurements of root and tubular
ascending aorta are made in the left parasternal long-axis
view (Figures 6 and 7), but other views such as left
‘‘high’’ parasternal and right parasternal are complementary and recommended. For TEE, the midesophageal
long-axis view and high-esophageal mid-ascending aorta
view are used (Figure 12). Both TTE and TEE modalities
have the disadvantage of potentially measuring obliquely
and not perpendicular to the long axis of the tubular
ascending aorta, which could render inaccurate aortic diameter measurements.
MRI and CT acquire 3D fields of view, and thus the aorta
diameter should be measured with multiplanar reconstruction to obtain double-oblique cross-sectional views of the
vessel (perpendicular to the longitudinal axis of the aorta).
The double oblique view corrects for measurement errors
caused by projecting the 3D aorta on a 2D screen. For the
same reason, it is recommended that ascending aortic diameters 45 mm or greater obtained by echocardiography be
further investigated by electrocardiogram (ECG)-gated
MRI or CT angiography during diastole. CT or MRI may
be performed in patients with aortic dilation (ie, 4044 mm) and poor-quality echocardiographic images.
Recommended CT and MRI measurement locations are displayed in Figure 11. If measurements are comparable and
reproducible between techniques, then future interval measurements can be obtained by TTE alone, with repeat CT or
MRI examination every 3 years to re-verify reproducibility
and agreement. If initial measurements are discrepant, then
CT or MRI should be the technique of choice for interval
aortic diameter measurements.
Regarding the aortic root, TTE measurements are consistently lower than those measured by ECG-gated CT angiography.160,161 This is particularly true for the asymmetric
dilated BAV root whose dimensions are frequently
underestimated by single 2D parasternal long-axis and standard short-axis TTE views. When root dilatation is visually
suspected by TTE or the root is significantly asymmetric,
we recommend measuring diastolic leading-edge to
leading-edge sinus-to-sinus diameters in parasternal shortaxis TTE view or alternatively go straight to CT/MRI
ECG-gated root assessment.
Because of the highly reproducible nature of ECG-gated
CT and MRI, these techniques should be used for accurate
assessment of aortic root measurements. However, it is
important to note that clinical cutoffs for intervention
largely have been derived from echocardiography,28 a difficult conundrum to reconcile.155 Nevertheless, akin to the
tubular aorta, echocardiography-derived aortic root diameters 45 mm or greater should be verified by ECG-gated CT
or MRI (Table 3). Given that the sinuses can dilate asymmetrically, all 3 sinus-to-commissure (or sinus-to-sinus) dimensions should be measured.162 The CT measurements
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FIGURE 6. Typical echocardiographic findings in a patient with BAV with tubular ascending aorta dilatation phenotype. A, Echocardiogram of a 60-yearold woman with R/N BAV, no aortic valve regurgitation, and a fusiform ascending tubular aortic aneurysm. Left parasternal long-axis view in diastole shows
root measurement of 36 mm (first arrow from left) and midtubular ascending aorta measurement of 47 mm (second arrow from left). B, Suprasternal diastolic view shows the mildly dilated proximal arch (36 mm, arrow) and normal upper descending aorta. C, Parasternal short-axis en face view of the aortic
valve in systole shows 2 commissures (asterisks) at 1 and 7 o’clock with right nonfusion. LV, Left ventricle; RV, right ventricle; Ao, aorta; PA, pulmonary
artery; RA, right atrium; LA, left atrium.

that correlate best with echocardiographic-derived values
are inner wall-to-inner wall dimensions, which require the
administration of contrast medium (Figure 11).163
The choice between CT and MRI is dependent on their
availability, institutional expertise, and age of the patient.
Younger patients (ie, <50 years) would benefit from MRI
to avoid CT-associated radiation exposure, but ECG-gated
MRI is not commonly performed in most institutions.
Ideally, interval measurements should be performed with
the same imaging modality and technique (ie, ECGgated), and compared side-by-side by an experienced
reader.155
It should be noted that radiologists occasionally recognize signs of BAV aortopathy in a patient with no previous
diagnosis of BAV. Suggestive signs are aortic leaflet

calcification at a young age (ie, <60 years) and an asymmetric shape to the ascending aorta, with bulging of the
outer curvature.164 Such patients should undergo TTE to
confirm the diagnosis.
C. Aortic Imaging Surveillance
After the first echocardiographic evaluation, the thoracic
aorta should be reassessed entirely on a yearly basis if
greater than 45 mm (Table 4). A first interval repeat measurement could be considered at 6 months before proceeding to yearly assessments, especially if other risk factors are
present, such as aortic coarctation or family history of
dissection. As opposed to Marfan syndrome in which the
aortic root is predominantly involved,51 the most common
segment involved in patients with BAV is the tubular

FIGURE 7. Patient with BAV with root phenotype aortic dilation. A, Echocardiogram of a 53-year-old man with R/L BAV, severe aortic valve regurgitation, and root-proximal ascending aortic aneurysm. Left parasternal long-axis view in diastole shows root measurement of 46 mm (arrow), STJ effacement
(asterisk), and proximal tubular ascending aorta dilatation. B, Left parasternal long-axis zoomed color-Doppler view in diastole shows the flow convergence
(arrow) of a posteriorly directed jet that quantified to 78 mL per beat of regurgitant volume. C, Parasternal short-axis en face view of the aortic valve in
systole shows 2 commissures (asterisks) at 4 and 10 o’clock with right-left fusion. LV, Left ventricle; RV, right ventricle; LA, left atrium; Ao, aorta; RA, right
atrium.
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FIGURE 8. MRI assessment of patients with BAV showing normal aortas (left) and different types of BAV aortopathy (middle and right). Each of the 3
upper panels shows maximum intensity projection of magnetic resonance angiography with the corresponding inferior panel demonstrating the planar analysis of systolic flow. The left panel demonstrates imaging from a normal patient. The middle panel demonstrates aneurysmal dilation at the level of the
sinuses with flow directed rightward and posteriorly in a patient with a left-right cusp fusion. The right panel shows more diffuse aneurysmal dilation in
a patient with right-noncoronary cusp fusion and flow directed leftward and posteriorly. RA, Right anterior; RP, right posterior; LA, left anterior; LP, left
posterior. Adapted from Burris and Hope.181

ascending aorta (ie, 60%-70% of BAV dilated aortas).28 It
is vitally important that images of any type not be compared
with the last prior image, but rather with the oldest prior image, which can be harder to access. Otherwise, gradual
growth can go undetected.165
Aortic growth rates for the tubular ascending segment in
adults with BAV have recently been reported to range from
0.4 to 0.6 mm/year,29,51 whereas earlier studies
demonstrated maximal dilatation rates of 1 to 2 mm/year.
Few patients are observed to have dilation rates of more
than 2 mm/year.29,51 Although these represent ‘‘artificially
annualized’’ rates, it remains unlikely that patients with
BAV will have dilation of 3 mm or more per year. It is
also important to note that an interval diameter change of
1 or 2 mm by current imaging modalities is within the
realm of error. Therefore, an interval dilatation of 3 mm
or more should be considered clinically significant.12

Absolute echocardiographic aortic diameters at baseline
are not reliable predictors of the rate of dilatation during
follow-up29,51; thus, regular interval imaging (Table 3) is
recommended regardless of baseline diameter. Previous
AVR is more common in patients with BAV presenting
with aortic dissection compared with patients with TAV
with dissection.166 Patients with BAV with previous AVR
have the highest reported risk of aortic dissection after
15 years of follow-up (ie, 1%),58 particularly if the original
operation was performed for BAV with aortic regurgitation.49 Therefore, continued interval monitoring of the unrepaired aorta post-AVR is suggested.

D. Abnormal Aortic Diameter Values and Indexing
The sinuses of Valsalva are normally larger than the STJ
and tubular ascending aorta, and the latter is larger than the
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13 cm2/m for the tubular ascending aorta and 10 cm2/m
for the root exhibited superior predictive accuracy for the
occurrence of dissection than absolute cutoffs.174 Another
indexed measure of the aorta, the ‘‘aortic size index,’’ in
which the maximum aortic size in centimeters divided by
the body surface area has been validated in a large database
of patients with aneurysm and was found to be more predictive of adverse events than maximum aortic dimension
alone.175 Likewise, a large database of patients with TAV
with aortic aneurysms found that indexed aortic size
improved the ability to predict long-term events.176 However, more research needs to be done to confirm these findings.

FIGURE 9. CT imaging with 3 dimensional reconstruction of a patient
with BAV with associated aortopathy.

arch and descending thoracic aorta. Normal values in adults
by age, body size, and gender have been reported for the
aortic root159,167 and tubular ascending aorta.159,168,169 An
aneurysm is defined as a permanent focal dilatation of an
artery having at least 50% increase in diameter compared
with expected.5,170 In clinical practice, however, it is
generally considered that a tubular ascending aorta greater
than 37 mm or aortic root greater than 40 mm represents
aortic dilation (but not aneurysm formation) in adult
patients.171
It is important to recognize that the aforementioned cutoffs are not absolute, such that 50 mm could represent moderate dilatation in a large man but may be severe dilatation
in a small woman. Thus, correction for body size parameters has been proposed (Table 3). Surgical repair has been
suggested for patients with Turner syndrome who have an
indexed aortic diameter of 2.75 cm/m2 or greater.172 The ratio of aortic cross-sectional area divided by height
[ratio ¼ r2 p(cm2)/height (m)] has also been proposed as
a method to correct for dissimilarities in body size.173 A ratio greater than 10 cm2/m has been recommended as the cutoff for elective aorta repair in both Marfan syndrome and
BAV disease,5 and a recent study involving 380 patients
with BAV with dilated aortas found that a cutoff of
e56

E. Emerging Imaging Technology and Imaging
Biomarkers
Imaging research for risk factors associated with BAV
aortopathy has primarily focused on degree of coexisting
aortic valve stenosis or regurgitation. These functional metrics alone do not reflect the rheologic burden on the aortic
wall due to BAV. With this in mind, a number of techniques
have shown promising initial results in the search for imaging biomarkers predictive of rheology-associated aortopathy development. For example, Della Corte and
colleagues153 investigated the valve opening angle obtained
via 2D balanced steady-state free precession cine images to
compute a proxy measurement for understanding the
impact of flow eccentricity on aortic growth. In this 36subject cohort, they found the fused leaflet opening angle
predicted ascending aorta diameters and growth rates. By
using a similar hypothesis, Burris and colleagues177
computed the barycenter of the velocity field from 2D
phase-contrast MRI to obtain ‘‘flow displacement,’’ a
parameter representative of the eccentricity of vessel
cross-section velocity field. The baseline displacement
measurement was found to be predictive of ascending aorta
growth in a small cohort of subjects.
With the use of insight from 2D phase-contrast MRI
studies,152 a number of investigators have assessed the rheologic forces at the aorta wall using 4D flow MRI and the
computation of WSS.89,178,179 These studies have directly
measured the impact of eccentric flow and their forces on
the aortic wall (Figures 13 and 14) and found correlations
to the aorta phenotype65 and regional tissue aortopathy.64,179 Although further study is needed, these
preliminary findings indicate that rheologically mediated
aorta remodeling is an important factor to consider in the
design of future studies.
6. INDICATIONS FOR SURGERY
The most important clinical decision for patients with
BAV-associated aortopathy is the appropriate timing of surgical intervention. Optimally, surgery should be recommended as soon as the risk of watchful waiting exceeds the risk
of surgical intervention. Unfortunately, the precise time
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FIGURE 10. Transthoracic assessment for aortic coarctation. A, Echocardiogram of a 31-year-old woman with BAV and severe aortic coarctation. Suprasternal systolic still frame shows laminar Doppler flow through the proximal portion of the arch (‘‘ARCH’’) before becoming turbulent flow across a tight
coarctation (arrow) just distal to the left subclavian (asterisk). B, Suprasternal diastolic still frame shows no Doppler flow through the proximal portion of the
arch but persistent diastolic turbulent flow across the coarctation (arrow) just distal to the left subclavian (asterisk). C, Continuous-wave Doppler signal
across the coarctation shows a systolic (measurement) peak gradient of 64 mm Hg through the coarctation, with persistent flow in diastole (arrow). D,
Pulsed-wave Doppler signal of the abdominal aorta shows a delayed peaking of the systolic signal (line) with prominent persistent flow in diastole (arrow),
pathognomonic of coarctation.

point when this occurs is patient- and surgeon-/center-specific and therefore oftentimes difficult to identify. Prophylactic aortic repair is recommended to prevent
catastrophic aortic complications, particularly aortic dissection and rupture. When examining data obtained from retrospective and natural history studies, it is important to
include patients experiencing sudden, unexplained cardiac
death as presumed (or at least possible) aortic
complications.
Factors that need to be considered when recommending
aortic repair include maximum aortic diameter, presence
of aortic risk factors (ie, rate of aortic growth, BAV phenotype, systemic hypertension, family history of aortic complications, or other aortic conditions such as coarctation
or connective tissue disorders), presence of surgical risk
factors (eg, advanced age, decreased left ventricular function, redo surgery), concomitant indications for cardiac surgery (most commonly aortic valvular stenosis or
insufficiency), and surgeon/team experience and level of

expertise. Although many different factors need to be
considered when making this clinical decision, it is worthwhile noting that operative risk usually plays a lesser role
for experienced aortic surgeons because the majority of patients with BAV are relatively young with few surgical risk
factors.
Despite the multitude of factors that need to be simultaneously assessed, we describe our general recommendations for surgical repair in patients with BAV with
aortopathy. For the purposes of clarity, indications have
been divided into patients with and without concomitant indications for AV surgery. In addition, recommendations for
management of the aortic arch are listed at the end of this
section.
A. Risk–Benefit Assessment of Additional Aortic
Repair: General Considerations
As in all surgical decision-making, the decision to repair
the aortic root or ascending aorta must be based on the
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FIGURE 11. A, Schematic shows the leading-edge to leading-edge measurement technique used in echocardiography, from left to right: measurement of the sinuses of Valsalva, STJ, and proximal tubular ascending aorta.
B, Inner-to-inner measurements used in MRI and CT. In addition, a consistent approach to measuring all 3 sinuses with MRI and CT is necessary. The
sinus-to-commissure and sinus-to-sinus measurements can both be used,
but consistency is necessary for interval surveillance. C, Standard measurement locations for MRI and CT with the inner-wall to inner-wall technique.
RCA, Right coronary artery; LCA, left coronary artery; MRI, magnetic resonance imaging; CT, computed tomography; DAo, descending aorta.

risk–benefit for a given patient in a given institution or surgeon’s hands. In this clinical scenario, the risk of any complications related to aortic surgery must be weighed against
the potential benefit from preventing aneurysm-related
complications. According to recent Society of Thoracic
Surgeons data, isolated ascending aorta replacement surgery is associated with a 3.4% risk of mortality and 3.2%
risk of stroke,183 whereas aortic arch surgery is associated
with a 5.1% risk of in-hospital mortality and 5.3% risk of
stroke.183 In contrast, the corresponding risks for isolated
AVR are 2.5% and 1.5%.184 Although the addition of an
aortic procedure to AVR is associated with no demonstrable
increase in morbidity or mortality at some large-volume
centers,185-187 this is not the case for most cardiac surgery
institutions. Center- and surgeon-specific volumes have
consistently been shown to have an influence on outcomes
in a wide variety of technically complex operations, and
aortic surgery is no exception. For instance, Hughes and
colleagues188 examined patients undergoing aortic root or
AVR plus ascending aortic replacement surgery and found
that operative mortality was 58% lower in high-volume
centers compared with low-volume centers.
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B. Indications for Aortic Repair in Patients With
Bicuspid Aortic Valve With Significant Aortic Valve
Dysfunction
For those patients with BAV with valve dysfunction significant enough to meet indications for AV surgery, the recommended cutoff for concomitant ascending aortic
replacement is 4.5 cm (Class IIa, level of evidence C in
AHA/ACC 2014 guidelines,9 ESC 2014 aortic guidelines,12
ESC valvular guidelines11) (Table 5). This recommendation
is primarily based on a retrospective study by Borger and
colleagues57 that showed a higher incidence of subsequent
aortic events in patients with BAV undergoing AVR with
an aortic diameter of 4.5 cm or more. It should be noted
that the majority of follow-up events were simple replacement of the ascending aorta during elective reoperative
AVR surgery. Another study supporting this cutoff showed
that the majority of patients with BAV status post-AVR who
developed aortic dissection had aortic dilation of 4.5 cm or
greater,166 and a second study demonstrated an increased
risk of dissection among patients with BAV with aortic dilation of 4.5 cm or more.33 The incidence of aortic dissection
and other aortic catastrophes post-AVR is low, particularly
in patients with BAV with AS.49,57
One argument supporting concomitant replacement of
the aorta during AV surgery, regardless of future risk of
aortic complications, is the fact that the aortic wall tends
to be quite thin when the diameter exceeds 4.5 cm. Therefore, surgeons may elect to replace the aorta in such patients, rather than risk experiencing catastrophic tears in
the suture line of an effaced aorta at the end of the procedure. In contrast, avoidance of prophylactic aortic repair in
patients with moderate aortic dilation (ie, 4.5-5.0 cm) is
prudent when extension of the myocardial ischemic time
should be avoided (eg, patients with poor left ventricular
function).

C. Specific Surgical Considerations for Patients
With Bicuspid Aortic Valve Undergoing Aortic Valve
Surgery
Most patients with BAV undergoing AVR do not require
aortic root replacement surgery. Indeed, the incidence of
significant aortic root dilation post-AVR in patients with
BAV is low, similar to patients with TAV disease.92,189,190
However, root replacement is recommended in patients
with BAV with an aortic root diameter exceeding
4.5 cm.26,57,155,191 Root replacement is oftentimes
required in patients with BAV presenting with acute aortic
dissection, because the proximal root is frequently
involved in the dissection process.32 However, performing
ascending aortic replacement alone and leaving a modestly
dilated root if the valve is intact may be prudent in patients
in extremis in whom an expedient operation may decrease
operative mortality.187 Leaving the root ‘‘for another day’’
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FIGURE 12. TEE aorta assessment. A, Prebypass echocardiogram of a 79-year-old man with typical BAV (right-left cusp fusion), mild AS, and severe
generalized aorta dilatation. High-esophageal mid-ascending aorta short-axis measurement (arrow) at 0 . B, Same imaging position as A, now at 91 , reveals
the mid-ascending aorta at 52 mm (long arrow) and the distal aorta (short arrow) at 49 mm. C, Mid-esophageal long axis at 127 allows measurements of the
proximal ascending aorta and root (dotted lines). D, Mid-esophageal long axis at 139 allows improved visualization of the root, which measured 49 mm
(dotted line). The patient underwent a Bentall procedure. Ao, Aorta; RPA, right pulmonary artery; RV, right ventricle; LV, left ventricle.

should not be considered a failure in surgery for acute aortic
dissection.
Patients with BAV may present with aneurysmal dilation
and effacement of the ascending aorta that extends preferentially into the noncoronary sinus. Such patients may be
effectively treated with a modified remodeling operation
with a tongue of graft extending into the noncoronary sinus.
Such an approach spares the patient from the added
complexity and increased risk associated with a complete
root replacement operation, and is associated with a low
rate of subsequent aortic events. Studies have shown excellent midterm results using this technique.192
Type of implanted valve at the time of AVR may influence the extent of aortic repair in patients with BAV. In patients with moderate aortic root dilation (ie, 4.5-5.0 cm)
who have opted for a mechanical valve, complete root
replacement is reasonable. Isolated AVR is preferable, however, in young patients who have opted for a biological
valve because of the low risk of subsequent aortic root
rupture/dissection92,190 and the increased technical
difficulty associated with repeat aortic root replacement
surgery.193

AVR surgery in patients with BAV may be complicated
by coronary anomalies, which are far more common than
in patients with TAV.194 The most common BAVassociated coronary anomaly is a nondominant right coronary artery, which can have implications for myocardial
protection during AV surgery. The position of the coronary ostia is also more variable in patients with BAV,
with ostia frequently positioned directly adjacent to an
aortic valve commissure. Such anomalies are important
to note preoperatively and may cause the surgeon to
take a less aggressive approach to aortic root repair in
such patients.
D. Role of Valve-Sparing Aortic Root Replacement
and Aortic Valve Repair
Patients with bicuspid aortopathy and relatively normal
aortic cusps with good mobility can be considered for
valve-sparing aortic root replacement surgery (ie, David
operation) in select centers. However, the indications for
aortic repair should be the same as for patients undergoing
more conventional forms of surgery (Table 5). With careful
patient selection, studies from high-volume centers have
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TABLE 4. Recommendations for interval monitoring imaging of the
aorta in patients with bicuspid aortic valve
Recommendation

Class/LOE

Interval imaging should be performed with the same
imaging technique and measurement method, and
compared side-by-side with previous study by an
expert in that imaging technique.

I/C12,155,159

Interval aorta imaging recommendations apply to
patients with native BAV and those who have
undergone AVR, given that aorta complications
may occur in patients with BAV postsurgery.

I/B58,166

In patients with normal initial aortic diameters by
TTE, the thoracic aorta should be reimaged every
3 to 5 y.

I/C51,155

In patients with initial aortic dilatation (root or
tubular ascending aorta measure 40-49 mm), the
thoracic aorta should be reimaged at 12 mo. If
stability is confirmed, then reimaging can be
performed every 2 or 3 y.

I/C12,29,51,155

In patients with more advanced initial aortic
dilatation (root or tubular ascending aorta measure
50-54 mm), the thoracic aorta should be reimaged
at least every 12 mo (yearly).

I/C12,51,155

If thoracic aortic dilation (45 mm) noted by TEE is
not reproducible with CTA or MRA (ie, >2-mm
difference between modalities), then interval
imaging follow-up should be performed with
MRA or CTA.

I/C155,159

LOE, Level of evidence; BAV, bicuspid aortic valve; AVR, aortic valve replacement;
TTE, transthoracic echocardiography; CTA, computed tomography angiography;
MRA, magnetic resonance angiography.

shown that valve-sparing aortic root replacement can be
performed in patients with BAV without increasing the
risk of reoperation or recurrent aortic regurgitation when
compared with patients with TAV.195-197 However, longterm results remain pending, and some have expressed concerns of increased long-term risk of AS or recurrent insufficiency.198-200 Further research insights into the different
BAV phenotypes will possibly shed more light on the
actual risk of these complications after repair/sparing
procedures. Given that valve-sparing aortic root replacement is more technically challenging in patients with
BAV, such operations should be performed in referral centers by surgeons with substantial clinical experience with
the David operation.
Isolated AV repair has also been applied in select patients
with BAV. On the basis of the pathophysiologic classification of aortic regurgitation developed by El Khoury and colleagues,201 various approaches to AV repair have been
developed.202,203 Although good midterm results in
patients with BAV have been demonstrated in expert
hands,204,205 debate continues regarding the optimal
method and even necessity of annular stabilization in such
e60

patients.206-209 Another topic of debate is the optimal
commissural geometry for AV repair in patients with
BAV.210-212 The lack of consensus regarding these issues,
the lack of long-term follow-up data, and the increased technical complexity of AV repair in patients with BAV have resulted in a lack of widespread adoption of these techniques
by the general cardiac surgery community.
E. Indications for Aortic Repair in Patients With
Bicuspid Aortic Valve Without Significant Aortic
Valve Dysfunction
Current guidelines recommend intervention on the aorta
in patients with BAV without significant aortic valvular
dysfunction (ie, valvular dysfunction does not meet criteria
for surgical valve repair/replacement) if the maximal aortic
diameter exceeds 5.5 cm and patients are lacking any highrisk characteristics (Table 5) (Class I, level B in AHA/ACC
guidelines9,10 and Class I, level C in ESC 2014
guidelines12). Such recommendations are based on the
observation that 6.0 cm represents a definite inflection point
in the risk of aortic complications in all patients regardless
of AV morphology213 and that natural history studies
demonstrating a definitively increased risk of such complications in those with BAV (vs TAV) are debatable. Although
Michelena and colleagues33 demonstrated that patients with
BAV have a higher risk of aortic dissection than the general
population, it is unknown at what aortic diameter these dissections tend to occur. In addition, the observation that
many patients with aortic dissection present with an aortic
diameter of less than 5.5 cm (ie, ‘‘aortic size
paradox’’)214,215 is difficult to interpret given that the
denominator size for this group of patients is large.213
Indeed, some studies of patients presenting with acute aortic
dissection have demonstrated larger ascending aortic diameters in patients with BAV,32,166 refuting the notion that the
BAV is less stable than the TAV. The larger aortic diameters
in patients with BAV may be a result of longer periods of
exposure to increased aortic shear stress in patients born
with a congenital anomaly, as opposed to acquired
disorders such as hypertension or atherosclerosis. Such an
explanation would be consistent with the increasing
amount of data supporting the hemodynamic theory of
BAV aortopathy, as opposed to the genetic theory (Section
3.A). It would also underscore the importance of ongoing
surveillance of the aorta in patients with BAV, with surgical
intervention being recommended only when appropriate
thresholds have been reached. These observations and the
definite, albeit low, risk of surgical intervention argue
against routine replacement of the aorta in patients with
BAV with smaller aortic diameters at the current time.
Certain factors may increase the risk of aortic complications in patients with BAV and therefore lead to earlier
intervention. Current guidelines recommend surgical intervention at an aortic diameter of 5.0 cm in patients with any
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FIGURE 13. A, 2D balanced steady-state free precession cine MRI showing the left ventricular outflow tract and the position of the aortic valve imaging
plane shown in yellow. B, TAV and the 2 most common BAV phenotypes: R/L and R/N cusp fusion. Arrows show the location of the raphe (if present) between the conjoined cusps. The conjoined R/L cusp (yellow box, arrow) is also seen to be doming in the corresponding left ventricular outflow tract view (A,
arrow). Bicuspidality of the aortic valve should be assessed in systole rather than diastole, because the valves often appear tricuspid when closed. TAV,
Tricuspid aortic valve; RL, right-left; RN, right noncoronary. Adapted from Entezari and colleagues.182

of the following risk factors: aortic coarctation, systemic
hypertension, a family history of aortic dissection, or rapid
aortic growth (>3-5 mm/year) in experienced hands. In the
AHA/ACC guidelines, this is a Class IIa, level of evidence

C recommendation,9,10 and in the ESC 2014 aortic
guidelines, this is a Class I, level C recommendation.12
Intervention at lower dimensions can be considered in patients with small body surface area or stature, particularly

FIGURE 14. MRI of a 73-year-old man shows the (A) balanced steady-state free precession valve cines of a patient with BAV with R/L fusion and no
stenosis. B, Contrast-enhanced magnetic resonance angiography shows mild dilation of the sinus of Valsalva with a maximal dimension of 40 mm and
(C) a 47-mm dilation of the mid-ascending aorta. D, An eccentric jet is observed downstream from the nonstenotic bicuspid valve that impacts along
the anterior portion of the tubular aorta. L, Left coronary cusp; N, noncoronary cusp; R, coronary cusp.
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TABLE 5. Recommendations for aortic repair in patients with
bicuspid aortic valve aortopathy
Recommendation

Class/LOE
26,27,33,155,226

Repair of the ascending aorta/root is
recommended when the aortic diameter is
55 mm in patients without risk factors

I/B

Repair of the ascending aorta/root should be
performed when the aortic diameter is
50 mm in patients with risk factors (ie,
root phenotype or predominant AI,
uncontrolled hypertension, family history
of aortic dissection/sudden death,
coarctation, aortic growth >3 mm/y)

IIa/B26,27,33,155,226

Repair of the ascending aorta/root may be
performed in patients with an aortic
diameter of 50 mm when the patients are
at low surgical risk and operated on by an
experienced aortic team in a center with
established surgical results.

IIb/C2,174

Concomitant repair of the ascending aorta/
root should be performed when the aortic
diameter is 45 mm in patients
undergoing cardiac surgery.

IIa/B26,33,57,155,166,191

Repair of the aortic arch is recommended in
patients with an aortic arch diameter of
55 mm.

I/B221,227

Concomitant repair of the aortic arch should
be performed in patients undergoing
cardiac surgery with an aortic arch
diameter of 50 mm.

IIa/C228

Concomitant repair of the aortic arch may be
performed in patients undergoing cardiac
surgery with an aortic arch diameter of
45 mm, provided the patients are at low
surgical risk and operated on by an
experienced aortic team with established
surgical results.

IIb/C220

It is recommended that patients undergoing
elective aortic arch repair be referred to an
experienced aortic team with established
surgical results.

I/B224,225

LOE, Level of evidence; AI, aortic insufficiency.

if they have Turner syndrome. Surgical repair is reasonable
in patients with Turner syndrome with an indexed aortic
diameter of 2.75 cm/m2 or greater.172 A similar indexed
aortic diameter cutoff175 or an aortic cross-sectional area
to height ratio of greater than 10 cm2/m174 may be used to
guide earlier surgical intervention in patients with small
stature. A lower threshold for aortic repair (ie, diameter of
5.0 cm) may be considered in women planning pregnancy
because of an increased risk of aortic complications in
such patients.216 Finally, earlier intervention may be occasionally justified in patients with a strong preference for
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early surgery, particularly if their condition causes undue
emotional stress.
A statement of clarification on management of aortopathy in BAV, released by the AHA/ACC in 2016, also recommended surgery if the aortic diameter is 5.0 cm or
greater, the patient is at low operative risk, and the operation
is performed by an experienced aortic surgical team in a
center with established expertise (class IIa, level of evidence B).10 Masri and colleagues2 found that surgical intervention in patients with BAV restored them to a normal
population survival curve and that patients with an aortic
diameter greater than 5.0 cm who did not undergo operative
repair had a modestly increased risk of death or aortic
dissection during follow-up. However, the perioperative
mortality in this study was only 0.4%. Wojnarski and colleagues,174 from the same center, also demonstrated a
modestly increased risk of aortic dissection starting at
5.0 cm in patients with BAV, with a more pronounced increase in risk starting at 5.5 cm. On the basis of these findings, the current document makes a class IIb, level of
evidence C recommendation for surgical repair of lowrisk patients in experienced aortic centers if the aortic diameter is greater than 5.0 cm (Table 5).
These recommendations reflect a general change toward
a more conservative approach for BAV-associated aortopathy when compared with previous guidelines, which stated
that such patients should be managed as aggressively as
those with connective tissue disorders.5 Studies published
subsequent to these earlier guidelines have demonstrated
that patients with BAV have a markedly lower risk of aortic
complications and aortic dilation than those with Marfan
syndrome.7,33,51 A recent joint statement of clarification
was published to address these issues.10
Recent evidence suggests a marked difference in the
natural history of patients with BAV with aortic regurgitation compared with stenosis. Girdauskas and colleagues86 found that the 10-year freedom from adverse
aortic events (dissection/rupture, death, and need for
proximal aortic surgery) was 78% in BAV with aortic
regurgitation versus 93% in patients with BAV stenosis
patients. Wang and colleagues217 recently confirmed
these results in a retrospective study. Other studies have
demonstrated more rapid progression of BAV aortopathy
in patients with aortic root phenotype (ie, dilation with
greater diameter at the sinuses of Valsalva than the
tubular ascending aorta, typically associated with aortic
regurgitation; Section 3.C).29,51,82 In addition, a metaanalysis found patients with BAV with aortic regurgitation to be 10 times more likely to experience aortic
dissection than those with AS.218 Therefore, it is reasonable to consider aortic repair in patients with BAV with
aortic regurgitation and root phenotype of aortic dilation
at an aortic diameter of 5.0 cm. Such patients may particularly benefit from a valve-sparing aortic root
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replacement (David) operation, if done in an experienced
center with known outcomes.
F. Management of Aortic Arch
In contrast to the ascending aortopathy, the natural history of the aortic arch in patients with BAV is not well established. Although there is correlation between BAV
morphology (eg, Sievers type 1, R/L) and proximal aortic
aneurysm, the association with regard to aortic arch pathology is less clear.219 Although some investigators
have found a correlation among Sievers type 1, R/N, and
aortic arch dilation,13,68 this association is not consistent.
The relative lack of natural history studies is further
confounded with the denominator neglect phenomenon,
whereas a few studies report the complications of aortic
arch aneurysm (eg, numerator).13,219,220 Data are lacking
on the risk of development of aortic arch pathologies
with BAV (eg, denominator). Furthermore, the gap in
knowledge also applies to nonsize criteria for
intervention, such as risk factors, genetic clusters, aortic
wall thickness, and strain measurements for patients with
BAV.
BAV aortopathy has been briefly addressed in multiple
guidelines and consensus statements, but most do not
address the aortic arch specifically. Neither the 2010
ACC/AHA guidelines5 nor the ESC guidelines12 discuss indications for aortic arch repair in patients with BAV. The
2014 Canadian Cardiovascular Society Position statement
was the first to recommend a threshold of 5.5 cm for
replacement of aortic arch aneurysm associated with
BAV.221
I. Aortic arch dissection
According to the International Registry of Acute Aortic
Dissection registry, the risk that the aortic arch is involved
during acute type A aortic dissection is lower in those
with BAV than TAV and Marfan syndrome.222 Furthermore,
a Mayo clinic study reported that among patients with
known aortic dilatation before dissection, the mean diameter was lower for those with TAV compared with
BAV.166 One can conclude from these observations that patients presenting with acute aortic syndromes (acute dissection, intramural hematoma, or penetrating atherosclerotic
ulcer) of the aortic arch should be treated following the recommended guidelines for these pathologies, regardless of
the aortic valve morphology.
II. Aortic arch aneurysm
There is controversy regarding the indication for surgical
therapy in aneurysmal aortic arch disease in patients with
BAV. Although experts agree that symptomatic aneurysmal
aortic arch disease should be treated regardless of size, there
is disagreement in regard to the asymptomatic patient and
the extent of the distal aortic repair.
Park and co-authors220 reported on a series of 422 patients with BAV undergoing replacement of the ascending

aorta without intervention on the aortic arch. These patients
were followed up for a median of 4 years with no reoperations for arch dilatation. They concluded that subsequent
enlargement of the aortic arch after ascending aortic
replacement is rare.220 They recommended tailoring the
extent of distal aortic operation in patients with BAV and
avoiding arch repair if the transverse arch is not significantly enlarged (ie, 4.5 cm).220
A contrarian view has been expressed from investigators
at Stanford University.13,219 With a study based partly on
embryological studies showing migration of cells of
neural crest origin into the aortic arch, Fazel and coauthors13 performed hierarchical cluster analysis and found
5 distinct patterns of aortic involvement in 127 patients with
BAV. In clusters III and IV, they found more frequent
involvement of the aortic arch and therefore recommended
aggressive hemiarch or total arch replacement in experienced centers. However, this study did not provide longitudinal information about the fate of the various clusters.
Furthermore, the amount of arch dilation found in such patients (median of 3.5 cm in cluster III) was well below the
recommended thresholds for aortic arch repair.
Malaisrie and colleagues223 recently advocated extending resection into the arch when the distal ascending or
proximal arch was larger than 4.0 cm.223 They compared
177 patients who underwent hemiarch replacement with
207 patients who received isolated ascending aortic replacement. The mortality rate increased from 1.5% to 3.0% in
the hemiarch group, although the difference did not reach
statistical significance in this small series. However, there
was a statistically significant 54% increase in cardiopulmonary bypass times and 35% increase in crossclamp times in
the hemiarch group.
This information suggests that indications for repair of
the aortic arch should be no different in the setting of
BAV compared with TAV. If a patient with BAV presents
for AVR and has an ascending aortic aneurysm with a
normal aortic diameter below the takeoff of the innominate
artery, ascending aortic repair without arch intervention is
recommended. If the aortic arch has a diameter of greater
than 4.5 cm at the innominate artery takeoff, hemiarch
replacement is reasonable in experienced centers, with the
understanding that operative mortality and risk of stroke
may be mildly increased. A total arch replacement is
reasonable in patients with BAV undergoing AVR with a
mid-aortic arch diameter of 4.5 cm or greater at the level
of left carotid artery as measured by 3D aortic centerline reconstructions. However, such pathology is rare and usually
found in patients with BAV with other causes of aortic arch
dilation (eg, previous aortic coarctation repair, concomitant
connective tissue disorder or Turner syndrome, chronic
aortic dissection). Given the complexity of the latter operations, a referral to experienced aortic centers is recommended. In emergency situations (eg, aortic dissection), even
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experienced aortic surgeons may wisely opt to avoid
compete resection of the diseased aorta and deal only
with the most critical aspects of the procedure. Complete
resection of all affected aorta, if necessary, can then be
considered electively at a later time.
III. Operative volume and outcome
Situations in which an operation should be extended to a
more aggressive approach should take into consideration
the expertise and comfort level of the surgeon and the experience of the center. One set of previously published guidelines attempted to define an experienced aortic center, but
the recommended benchmark mortality rates (ie, <1% for
elective repair of ascending aorta and aortic root aneurysm
repair) is far below most reported series.221
A Japanese cooperative study examined 2875 patients
undergoing thoracic aortic surgery in 36 centers between
2003 and 2005224 and found an important impact of hospital
and surgeon volume on operative mortality. They found in
young patients (<65 years of age), outcomes improved
with increased hospital volume.224 Risk-adjusted mortality
was 10% for centers performing less than 20 thoracic aortic
operations during a 3-year period compared with 4% for
centers performing more than 20 operations.224 In addition,
observed outcomes in high-risk patients (ie, Japan Adult
Cardiovascular Surgery Database predicted risk of mortality 6%) improved with increased hospital volume.224
Risk-adjusted mortality in these high-risk patients was
20% for centers performing less than 20 thoracic aortic operations, compared with 12% for centers performing more
than 20 operations.224 Gazoni and colleagues225 also
compared low-volume centers (<40 cases in 3 years) with
high-volume centers (>80 cases in 3 years) in the Virginia
Cardiac Surgery Quality Initiative. They found no difference in mortality for ascending aneurysm with valve procedure (3.4% high vs 5.2% low, P ¼ .40), but increased
mortality in low-volume centers for isolated ascending aneurysms (17% vs 3%, P ¼ .01) and arch aneurysms (25%
vs 5%, P ¼ .01).225 Thus, ascending aortic replacement
with or without aortic arch repair may be associated with
a higher complication rate than previously identified in centers with limited experience. By taking into account these
findings, patients requiring more extensive aortic repair
involving the aortic arch should be referred to a center of
expertise for nonemergency surgery.
7. SURGICAL FOLLOW-UP, MEDICAL
MANAGEMENT/WATCHFUL WAITING, FAMILY
SCREENING
The current section provides information regarding management and radiologic follow-up of patients with BAV undergoing watchful waiting, as well as patients with BAV
who have undergone aortic repair surgery. Recently published guidelines and review articles on the subject may
also be instructive.18,221
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A. Imaging Postsurgery
Imaging of the aorta soon after initial surgical repair is
aimed at detecting anastomotic leaks and pseudoaneurysms, as well as establishing a baseline for future comparisons. For this purpose, an ECG-gated cardiac CT is
preferred to TTE because echocardiography is often
limited by the presence of prosthetic aortic valves and
provides incomplete aortic imaging. In younger individuals (<50 years of age), however, MRI may be preferable to repeat CT examinations to avoid the risk of
radiation-induced malignancy. Furthermore, in the
setting of acute aortic syndromes, MRI is particularly
helpful in distinguishing mural thrombus from intramural blood.229,230
The interval at which repeat imaging is performed after
aortic surgery is often dictated by the extent of the initial
operation and whether areas of aortic dilatation were not
addressed during the initial surgery. For example, if a
supracoronary graft replacement was performed in the
setting of a moderate root dilatation that was not addressed, then the imaging surveillance interval may be
shorter. A similar situation may arise if a moderately
dilated aortic arch was left untreated during replacement
of the ascending aorta or if limited resection was performed in the setting of a type A dissection. In patients
who underwent complex hybrid reconstructions of the
aorta (ie, debranching combined with endovascular
repair), more frequent imaging is also advisable. In the
absence of residual aortic dilation/pathology, it is reasonable to suggest that the entire aorta be imaged by CT or
MRI once every 3 to 5 years after aortic repair (Table 6).
When possible, these studies should be performed at the
same institution using similar imaging techniques and protocols to minimize variation.

B. Medical Management and Watchful Waiting
The medical management of patients with BAV aortopathy who are subject to ongoing watchful waiting is usually
focused on blood pressure control and overall cardiovascular risk reduction via pharmacologic and nonpharmacologic
measures. The rationale for antihypertensive therapy is
based on mechanistic and animal studies,231,232 as well as
observational reports linking aortic dissection to
hypertension.233,234 In patients with BAV aortopathy, there
are no randomized trials or observational studies to help
guide decision-making. Treating hypertension with betablockers or inhibitors of the renin-angiotensin system has
been suggested, based largely on extrapolation of data
from Marfan cases.18,221 At the present time, there are no
data to support lower blood pressure thresholds for
patients with dilated aortas in the setting of BAV;
therefore, country- and region-specific guidelines for treatment of hypertension should be followed. Target blood
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TABLE 6. Recommendations for postsurgical repair, medical
management, and watchful waiting
Recommendation

Class/LOE

Radiologic imaging (with CTA or MRA) may
be performed after aortic surgery to
establish a postrepair baseline.

IIb/C

Ongoing postoperative surveillance intervals
should be individualized on the basis of the
clinical, anatomic, and surgical features. In
the presence of residual aortic dilation/
pathology, it is reasonable to image the
entire aorta every 3-5 y by CT or MRI after
repair.

IIa/B12,29,51,58,155,166

MRI should be considered for repeat
examinations in an adolescent or in the
adult population aged <50 y.

IIa/B159

Treatment of hypertension is recommended
according to country- and region-specific
guidelines.

I/C52-54,155,250,251

Beta-blockers and inhibitors of the reninangiotensin system should be considered
for blood pressure control based on
evidence extrapolated from populations
with connective tissue disease.
Nonpharmacologic approaches (salt
reduction, weight reduction) should be
advocated as part of blood pressure control
strategies.

IIa/C52-54,155,250,251

Patients with aortic aneurysms that are at or
near surgical thresholds for correction
should avoid strenuous lifting, pushing, or
straining that would require a Valsalva
maneuver.

IIa/C5,221,241,242,252

It is recommended to avoid heavy weight
lifting or competitive athletics involving
isometric exercise when the ascending
aortic diameter is >45 mm.

I/B5,221,241,242,252

Patients with BAV and dilated aorta should be
precluded from private driving if the
ascending aorta diameter is >6.0 and
restricted from commercial driving if the
ascending thoracic aorta diameter is
>5.5 cm.

IIa/C221,240

It is recommended that prepregnancy
evaluation and postpregnancy
management of women with BAV with or
without associated aortopathy be
performed by practitioners with expertise
in the management of pregnant women
with heart disease.

I/C253

First-degree relatives of patients with BAV
should undergo screening
echocardiography.

IIa/B249

LOE, Level of evidence; CTA, computed tomography angiography; MRA, magnetic
resonance angiography; CT, computed tomography; MRI, magnetic resonance imaging; BAV, bicuspid aortic valve.

pressure thresholds in individuals without diabetes, aged
more than 60 years, and with multiple risk factors are likely
going to change after the results of the SPRINT trial, which
demonstrated a reduction in overall cardiovascular mortality with an intensive blood pressure target of 120/80 mm Hg
in such individuals.235 Although clinical data are lacking, it
may be reasonable to achieve these targets in subjects who
do not meet the SPRINT criteria who have specific factors,
including patient or family history of acute aortic syndrome
or sudden death, or aortic aneurysm growth despite medical
therapy.
In patients with chronic aortic dissection, observational
reports suggest lower risk for operative repair with betablocker therapy.236 In patients with type A and type B aortic
dissections, beta-blockers are associated with improved survival.237 Use of calcium-channel blockers has also been
associated with improved survival in type B aortic dissections,237 as well as decreased rate of aortic expansion.238
One study identified an association between angiotensinconverting enzyme inhibitor and better survival in patients
with type B aortic dissection,239 although this was not
confirmed in a more recent study.237
General counseling on nonpharmacologic approaches to
risk reduction should be part of watchful waiting in those
with BAV aortopathy. Such recommendations include
limiting salt intake (to reduce hypertension), a diet low in
saturated fats, exercise (with caveats, discussed later), and
smoking cessation. Management of dyslipidemia should
follow regional or national guidelines based on primary or
secondary prevention thresholds and targets, where
applicable.
There are no specific recommendations regarding automobile driving within the 2010 ACC/AHA guidelines.5
However, the Canadian Medical Association has recommended that patients with abdominal aortic aneurysm be
precluded from driving when the rupture risk exceeds
10% per year. On the basis of the best observational data
available, these thresholds of risk occur for thoracic aortic
aneurysms greater than 6.0 cm in the ascending aorta or
arch, and greater than 6.5 cm in the descending aorta.175
A lower threshold for rupture risk is reasonable for commercial driving.221,240
Exercise prescription or restrictions should be individualized in patients with aortic aneurysms. Patients with previously repaired aortic dissection should avoid strenuous
lifting, pushing, or straining that would require a Valsalva
maneuver.5,221,241,242 Strenuous strength training may be
dangerous for patients with BAV aortopathy, because
aortic dissection has been linked to weight lifting.242 The
proposed mechanism is transiently elevated blood pressure
associated with isometric exercise or Valsalva maneuver.241
Heavy weight lifting or competitive athletics involving isometric exercise may trigger aortic dissection; therefore,
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such activities should be avoided in patients with moderately dilated aortas (ie, >4.5 cm) or when there has been a
significant interval increase in aortic size. However, individuals with bicuspid aortopathy can and should undergo aerobic or endurance exercise, because these exercises are
beneficial for blood pressure lowering.243 If patients want
to engage in vigorous aerobic exercise, such as running or
basketball, one might consider performing a symptomlimited stress test to ensure that the patient does not have
a hypertensive response to exercise. In patients with a
normal bicuspid valve and no associated dilated aorta, no
restrictions of activity are required.
The management of pregnancy in the setting of BAV is
not well studied, and this area has been recently summarized in a review.18 In general, women with BAV should undergo imaging of the entire aorta before pregnancy,244 and
prepregnancy evaluation in women with known BAV aortopathy should be performed by practitioners with expertise
in the management of pregnant women with heart disease.
The exact threshold to recommend against pregnancy is
not known, but it would reasonable to suggest that if the
ascending aortic diameter is close to the threshold of surgical intervention, then the risks and benefits should be
weighed and individualized decisions be made. Some
studies have suggested that women with ascending aorta
or root dimension greater than 4.5 cm should be advised
against pregnancy, although this is controversial.180,221 A
thorough interdisciplinary, team-based approach is recommended to discuss case-by-case scenarios.
Pregnant women with a dilated aorta, including BAV
aortopathy, should have strict blood pressure control and
repeated echocardiographic imaging every 4 to 12 weeks
during pregnancy.244 MRI (without gadolinium) is recommended if there is an indication for imaging of the distal
ascending aorta, aortic arch, or descending aorta during
pregnancy. TEE is an alternative to MRI for imaging of
aorta during pregnancy.
Beta adrenergic blockers, to reduce shear stress on the
aorta, may be considered during pregnancy in women
with a dilated aorta. Women with bicuspid aortopathy or
history of aortic dissection should deliver in a center where
cardiothoracic surgery is available.244 The type of delivery
(eg, Caesarean section) and peripartum anesthetic requirements should be determined in advance by the obstetrics
and anesthesia teams.
C. Family Screening
Most cases of BAV disease are sporadic, but familial
clustering has been a long-recognized phenomenon.245 Genetic studies have suggested an autosomal dominant pattern
with incomplete penetrance and variable expressivity as the
likely mode of inheritance.246 However, the preponderance
of male patients with BAV and the association with Turner
syndrome have suggested an X-linked pattern.247 Several
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different gene mutations have been linked to BAV disease,
including NOTCH1, TGF-ß2, ACTA2, FNB1, KCNJ2,
GATA5, Nkx2-5, and SMAD6.248 The degree of genetic
heterogeneity is not surprising, given the marked heterogeneity of clinical findings in patients with BAV.
The heritability of BAV disease is more than 80%, and
approximately 9% to 15% of first-degree relatives have
the disorder.249 Therefore, it is recommended that firstdegree relatives of patients with BAV are screened with
echocardiography.
8. KNOWLEDGE GAPS AND FUTURE RESEARCH
Key questions remain unanswered with respect to
BAV-associated aortopathy. First, specific genetic and
developmental causes of the congenital bicuspid valve malformation itself remain unclear. A thorough genetic understanding has been especially elusive, likely reflecting
multifactorial genetic mechanisms. This critical gap in
knowledge influences the understanding of the wider spectrum of manifestations of BAV-related diseases, including
the heterogeneous expression of different phenotypes of
BAV aortopathy. It is reasonable to assume that the underlying pathogenesis of the bicuspid valve itself may play a role
in the propensity, development, and progression of BAV
aortopathy. Further investigations of these root causes are
necessary for a more complete understanding of bicuspid
aortopathy. Second, the causes of valve dysfunction in the
majority of patients with BAV over time are unclear. Likewise, the causes of BAV aortopathy in many, but a smaller
proportion of, patients with BAV remain elusive. Third,
the marked clinical heterogeneity of BAV disease and the
specific risk factors that predispose individual patients
with BAV to valve dysfunction or to aortic dilatation/dissection remain mysterious. Further research to clarify the pathophysiology of BAV disease progression and to more
precisely identify risk profiles for individual patients with
BAV is needed. Addressing these knowledge gaps could
dramatically change our clinical and surgical approach to
BAV aortopathy.254
Advances in knowledge may have been hampered thus
far by a circuitous debate about the pathogenesis of BAV
aortopathy as ‘‘genetic’’ versus ‘‘hemodynamic.’’ In light
of the increasing recognition of the heterogeneity of BAV
aortopathy, this dichotomy has begun to be questioned.82,255
In a recent study, aortic dilatation progressed at a yearly rate
that varied within a wide range in a cohort of patients with
BAV followed for 3 years, and did not progress at all in 43%
of them.51 This marked heterogeneity suggests a more complex pathogenesis than just ‘‘genetically determined’’ or
‘‘hemodynamically driven.’’ Both genetic variants and
rheological abnormalities may coexist, resulting in diverse
clinical phenotypes with distinct natural histories.
Most studies on BAV aortopathy generally disregarded
the described heterogeneous nature of BAV disease in terms
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of clinical features (age of onset, velocity of progression,
risk of acute events), valve morphology, and phenotypes.
Future studies on BAV aortopathy should be adequately designed to differentiate among distinct forms of the disease.
Another common limitation of previous research in this
field is the observational nature of the majority of previous
studies. Such retrospective studies report the association of
clinical factors, flow features, histopathology, or molecular
findings with aortic dilatation in patients with BAV and
consequently infer their role in the underlying pathogenesis.
However, it is unclear whether the associated findings are a
consequence of the dilatation itself rather than a determinant or risk factor.256 Future research must advance beyond
associative studies toward more informative mechanistic investigations, functional studies, and experimental validations. Clinical randomized trials, particularly of
pharmacologic treatments to slow the progression of aortic
dilatation or prevent acute events, are particularly warranted. However, conducting these studies will be challenging because of the slow progression of BAV disease
and the need for large cohorts to account for the different
phenotypes. Nevertheless, multisite longitudinal studies
that link clinical, genetic, and hemodynamic risk factors
to patient outcomes are urgently needed.
Clinical studies may be confounded by patient referral
patterns or selection criteria for enrollment. These issues
may explain contradictory studies, which are common in
the field of BAV research. Clinical features of BAV aortopathy can vary according to whether they are analyzed in
population studies or with specific hospital referral patterns,
as well as between surgical and nonsurgical studies. Failure
to account for these confounding factors and sources of bias
can lead to misleading conclusions.
Another limitation of past research on BAV aortopathy
has been the use of inconsistent or ambiguous terminology, making it difficult to compare results between
studies.93,257 In addition, many clinical series were
obtained from single-center experiences with a limited
number of patients observed. Future collaborative multicenter efforts with clearly defined terminology are warranted. Such studies may be spearheaded by
international organizations, such as the recently established Bicuspid Aortic Valve Consortium research
group.28 Previous studies, especially those on molecular
and cellular aspects, tended to address novel pathways
and pathogenetic hypotheses rather than verify and expand
previously acquired knowledge. Thus, various findings
from different research efforts cannot converge into the
establishment of a definite pathogenetic sequence, that
is, all the subsequent mechanistic steps from the first
cause to the ultimate effect. It may be necessary to merge
large amounts of patient data and different investigators’
expertise to ensure adequately powered study populations
and correct study designs.

At the present time, the greatest unmet clinical research
need is the identification of optimal criteria for risk stratification. Prognostic stratification of BAV aortopathy suffers
from 2 important issues: the gaps in knowledge on the pathogenesis of bicuspid aortopathy and the unknown mechanisms of acute aortic complications, namely, aortic
dissection. It has been demonstrated that dissection occurs
in the majority of cases at aortic sizes well below the
threshold recommending prophylactic aortic resection,258
although this observation can be explained by the ‘‘size
paradox.’’213 Some investigators have advocated nondimensional criteria for risk stratification.259 These should
be derived from the validation of novel methods to detect
aortopathy in its early stages and predict aortic disease
development via preclinical aortic wall dysfunction or
aortic tissue disarray. Circulating biomarkers that are associated with aortopathy may be particularly helpful in this regard, although preliminary studies in this area have not been
fruitful. A greater prognostic armamentarium would support a patient-specific approach to BAV aortopathy,59,69,254
especially in terms of criteria informing surveillance,
surgical indications, and follow-up. Future advances may
be best achieved using emerging diagnostic imaging modalities, such as 4D-flow MRI and computation fluid dynamics,143 possibly combined with novel molecular
biomarkers.259
9. CONCLUSIONS
Research on BAVaortopathy is challenging for many reasons. There remain significant gaps in our current knowledge that limit best practices and adherence to clinical
guidelines. Future investigations should account for epidemiologic and phenotypic heterogeneity of the disease.
Multicenter and multidisciplinary teams should be leveraged to perform robust hypothesis-driven analyses.28 Basic
and translational approaches may help inform clinical
studies.
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